ABL1 M351T

CI-VAR-00002589Explore in graph →NP_005148.2:p.Met351ThrNM_005157.5:c.1052T>CClinVar 12629 CIViC 1029 rs121913457

Curated evidence

Evidence by cancer (21 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–21 of 21 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Chronic Myeloid Leukemia, BCR-ABL1 Positive19
BCR::ABL1 Fusion AND ABL1 M351T	Axitinib	Predictive	D	Supports Resistance	2	accepted	EID4399 In an in vitro study, pro-B Ba/F3 cell line expressing M351T mutation in the ABL1 portion of the BCR-ABL1 fusion protein (overexpression) demonstrated resistance to axitinib treatment (IC50: 920.2nM),… (full text at CIViC) PMID 26582647 · Zabriskie et al., 2016 · Open in CIViC	civic
BCR::ABL1 Fusion AND ABL1 M351T	Axitinib	Predictive	D	Does Not Support Resistance	2	accepted	EID7769 In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed decreased incorporation when harboring fusions with t… (full text at CIViC) PMID 25686603 · Pemovska et al., 2015 · Open in CIViC

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
12629	Pathogenic	no assertion criteria provided	0	Chronic myeloid leukemia	germline	1	Aug 01, 2002	clinvar

Malignant Neoplasm2
BCR::ABL1 Fusion AND ABL1 M351T	Imatinib	Predictive	D	Supports Resistance	3	accepted	EID7841 In an in vitro study, a Ba/F3 cell line stably expressing the M351T mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to imatinib treatment (IC50: >2000.0 nM) … (full text at CIViC) PMID 18191450 · Deguchi et al., 2008 · Open in CIViC	civic
BCR::ABL1 Fusion AND ABL1 M351T	Bafetinib + Dasatinib + NilotinibSubstitutes	Predictive	D	Does Not Support Resistance	3	accepted	EID2686 In an in vitro study, a Ba/F3 cell line stably expressing the M351T mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with similar sensitivity to nilotinib, dasatinib, and baf… (full text at CIViC) PMID 18191450 · Deguchi et al., 2008 · Open in CIViC	civic